PAP Adherence Lowers ER Visits for Sleep Apnea Patients with Heart Failure 

People with heart failure and obstructive sleep apnea (OSA) can significantly reduce hospitalizations and emergency room visits as well as related costs by being adherent to positive airway pressure (PAP) therapy, according to two studies supported by ResMed and presented at SLEEP 2023. One retrospective study showed people with OSA and systolic heart failure and…

Read More

Harmony Announces Positive Phase 2 Data on Pitolisant for Prader-Willi Syndrome

Harmony Biosciences Holdings Inc presented safety and efficacy data from a phase 2 proof-of-concept study evaluating pitolisant for the treatment of excessive daytime sleepiness in people with Prader-Willi syndrome at SLEEP 2023.  The positive signal supports further development to determine if pitolisant has the potential to address an unmet medical need for people with Prader-Willi…

Read More

Avadel Announces US Launch of Lumryz for Narcolepsy

Avadel Pharmaceuticals plc announced that Lumryz—an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy—is now commercially available.  “We are proud to announce that Lumryz is commercially available through both our RYZUP patient support program and our specialty…

Read More